JERUSALEM--(BUSINESS WIRE)--Speaking today at the BIO CEO & Investor Conference 2007, Morris C. Laster, MD, CEO of BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, announced the successful completion of Phase 1 clinical trials of its most advanced drug, BL-1020, the first GABA enhanced antipsychotic for the treatment of schizophrenia. The study results showed that BL-1020 was well tolerated and showed an improved safety profile reducing extrapyramidal symptoms that are experienced with currently available therapies.
